日本化学療法学会雑誌第56巻第4号

Similar documents
Fig. 1 Table l l l l l l l l l l l l l l l l l l l l l l l l l l

日本化学療法学会雑誌第57巻第1号

日本化学療法学会雑誌第61巻第6号

生活設計レジメ

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

I II III 28 29


- 1 -

Acecide_ProductsInformation2010PDF.indd

l Fig. 1


エコリシン点眼液/眼軟膏インタビューフォーム

日本化学療法学会雑誌第64巻第4号


i


Wide Scanner TWAIN Source ユーザーズガイド

2016.

第121回関東連合産科婦人科学会総会・学術集会 プログラム・抄録

I II III IV V

立命館21_松本先生.indd



立命館20_服部先生.indd




立命館16_坂下.indd



立命館人間科学研究No.10



立命館21_川端先生.indd

立命館14_前田.indd

立命館17_坂下.indd


立命館人間科学研究No.10



立命館19_椎原他.indd

立命館人間科学研究No.10

立命館19_徳田.indd


北海道体育学研究-本文-最終.indd

訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書

第1部 一般的コメント

第十五改正日本薬局方第一追補

内科96巻3号★/NAI3‐1(第22回試験問題)

untitled

表1票4.qx4

福祉行財政と福祉計画[第3版]

第1章 国民年金における無年金

橡ミュラー列伝Ⅰ.PDF

II III I ~ 2 ~

中堅中小企業向け秘密保持マニュアル


PR映画-1


- 2 -


1 (1) (2)

-Vol.88.3/前.indd

日本化学療法学会雑誌第58巻第4号

provider_020524_2.PDF

tnbp59-21_Web:P2/ky132379509610002944

「産業上利用することができる発明」の審査の運用指針(案)

Table 1 Table 2




CRS4

パーキンソン病治療ガイドライン2002


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

178 5 I 1 ( ) ( ) ( ) ( ) (1) ( 2 )

研修コーナー

抄録/抄録1    (1)V

untitled

untitled

Fig.1 Chemical structure of BAY o 9867

Original Article Abstract Key words


dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na

R06_01

2004/01/ /01/23 2 I /04/ /04/ ,-1-8-1,-2-2-1,-3-4-1,-3-5-1,-4-2-1, ,-5-6-1, _.doc 1

Microsoft Word - CATNewsVol5NoS4Text doc


‡È‡¢‡Ó‡éNo.46

四校_目次~巻頭言.indd

ii

untitled

i

<31315F985F95B62D899C8CA98E8182D982A92E696E6464>

AccessflÌfl—−ÇŠš1


untitled

1,

2

MF 型

Transcription:

Key words I

Number of xenobiotic transporters 25 20 5 0 5 0 Pseudomonas aeruginosa Escherichia coli Bacillus subtilis R MFS SMR MATE ABC Mycobacterium tuberculosis Fig.. Numberofputativedrugefluxgenesidentifiedby gemonicanalysis. Putativedrugefluxsystemsareclassifiedintofivetypes. Thedatabaseispostedat[htp:/www.membranetransport.org/]. II β macab III

R OM ABC MF SMR MATE Drug H H H Na / H IM ATP Drug ADP Pi Drug Drug Drug Drug ATP dependent Multi-component 2~ TMs TMs 2 TMs Fig.2. Classificationofdrugefluxsystems. Drugefluxsystemscanbeclassifiedintofivecategoriesbasedontheirstructureandcouplingenergies. ABC:ATPbindingcassete,R:resistancenodulationcel-division,MF:majorfacilitator,SMR:smalmultidrugresistance,MATE:multidrugandtoxiccompoundextrusion Fig.3. SubstratesoftheAcrAB-TolCdrugefluxsystem ine.coli. AcrAB-TolCsystem enhancesmultidrugresistanceofe.coli.thestructuresofcompoundsrecognizedbythissystem areshownin Figure.NumbershowedthechangesMIClevelsandtheirincreasedratiowhenAcrAB-TolCisover-producedintheacrBmutant.

Table. DrugresistanceprofilesofefluxsystemsinE.coli Type Eflux System CP TC MINO EM -(Δ acrb) 0.390.39 0.20 ABC MacAB 0.390.39 0.20 MF Fsr 0.390.39 0.20 MdfA 6.25 0.20 MdtG 0.390.39 0.20 MdtH 0.390.39 0.20 Bcr 0.393.3 0.20 EmrKY 0.390.39 0.20 EmrAB 0.390.39 0.20 EmrD 0.390.39 0.20 MdtL 0.39 0.20 MdtM 0.39 0.20 R AcrAB 3.33.3 3.3 MdtABC 0.390.39 0.20 AcrD 0.39 0.20 AcrEF 6.253.3 3.3 MdtEF 0.390.39 0.20 SMR EmrE 0.390.39 0.20 MdtIJ 0.390.39 0.20 SugE 0.390.39 0.20 MATEMdtK 0.39 0.20 NA NFLX ENX KM FOM 25 0.025 0.05 6.25 3.3 0.20 0.05 6.25 3.3 0.025 0.05 6.25 6.25 3.3 0.05 0.0 6.25 3.3 0.025 0.05 25 6.25 3.3 0.05 0.05 6.25 003.3 0.0 0.39 6.25 3.3 0.05 0.05 6.25 3.3 3.3 0.05 0.052.5 3.3 2003.3 0.0 0.39 6.25 25 0.025 0.05 6.25 3.3 0.025 0.05 6.25 3.3 3.3 0.20 0.39 6.25 3.3 DXR MICforacrBmutant-overproducingefluxsystems(μg/mL) NOV TMP ACR BENZ DOC 3.3 3.3 2.5 3.3,250 0.39 3.3 3.3 2.5 3.3,250 0.39 3.3 6.25 2.5 3.3,250 2.5 3.3 00 3.3,250 0.39 3.3 3.3 2.5 3.3 2,500 3.3 3.3 2.5 3.3,250 3.3 3.3 25 3.3,250 3.3 3.3 2.5 3.3 0,000 0.39 3.3 3.3 2.5 3.3 0,000 0.39 3.3 3.3 2.5 6.25,250 3.3 3.3 2.5 3.3,250 3.3 3.3 50 3.3,250 > 200 00 > 00> 00 00 > 0,000 > 00 3.3 25 3.3 2.5 6.25 0,000 3.3 3.3 6.25 3.3 2.5 3.3 > 0,000 2.5 > 200 50 00 00 50 > 0,000 50 25 3.3 2.5 6.25 5,000 2.5 3.3 3.3 200 6.25,250 0.39 3.3 3.3 2.5 3.3 5,000 3.3 3.3 2.5 3.3,250 25 2.5 2.5 3.3 0,000 0.39 MPIPC MCIPC NFPC CBPC SBPC CXM CMD CAM 00 6.25 2.5 00 2.5 200 6.25 50 200 25 6.25 25 2.5 50 OL AZM FO BI CTP 0.20 0.0 50 0.39 25 20 0.20 0.0 2.5 00 2.5 2.5 0.20 0.0 00 0.20 0.0 0.20 0.0 0.39 0.20 0.0 0.39 0.20 0.39 0.20 0.0 0.20 0.0 60 0.20 0.0 Abbreviations:CP,chloramphenicol;TC,tetracycline;MINO,minocycline;EM,erythromycin;NA,nalidixicacid;NFLX,norfloxacin;ENX,enoxacin;KM,kanamycin;FOM,fosfomycin;DXR,doxorubicin;NOV, novobiocin;tmp,trimethoprim;acr,acriflavine;benz,benzalkonium;doc,deoxycholate;mpipc,oxacilin;mcipc,cloxacilin;nfpc,nafcilin;cbpc,carbenicilin;sbpc,sulbenicilin;cxm,cefuroxime; CMD,cefamandole;CAM,clarithromycin;OL,oleandomycin;AZM,azithromycin;FO,fosmidomycin;BI,bicyclomycin;CTP,cetylpyridinium.,notdetermined.

Fig.. Identifieddrugefluxsystemsandregulationbysignaltransductionsystems. Weidentified20drugefluxsystemsofE.colibyusinggenomicinformation.Wealsodiscoveredanovelresistancemechanism,the two-componentsignaltransductionsystem,whichregulatestheseefluxsystems. β IV Salmonella enterica

3,39 3,350 (kb) tolc 89.7% 529 530 53 532 533 (kb) acrb 9.6% acra 9.7% 2,59 2,595 2,596 2,597 (kb) acrd 9.3% 3,56 3,562 3,563 3,56 3,565 (kb) acre 87.5% acrf 88.7% 2,2 2,25 2,26 2,27 2,28 2,29 2,220 2,22 2,222 (kb) mdta 82.7% mdtb 9.6% mdtc 9.7% 393 39 395 396 397 398 (kb) mdsc ( STM0350 ) Nonexistent in E.coli 5.5% to OprM in P. aeruginosa 2,962 2,963 2,96 (kb) mdsb (STM035 ) Nonexistent in E.coli 62.3% to MexF in P. aeruginosa mdsa (STM0352 ) Nonexistent in E.coli 3.8% to MexE in P. aeruginosa emra 89.7% emrb 95.7% 938 939 90 (kb) mdfa 90.6%,502,503 (kb) mdtk 92.3% Gene encoding Outer Membrane Protein Gene encoding Membrane Fusion Protein Gene encoding R-type Efflux Protein Gene encoding MFS-type Efflux Protein Gene encoding MATE-type Efflux Protein Gene encoding ABC-type Efflux Protein,09,020,02 (kb) maca 83.2% macb 83.3% Fig.5. DrugefluxgenesencodedintheSalmonelaentericaserovarTyphimurium genome. Chromosomalpositionsofgenescodingforputativedrugefluxsystems,outermembranepro teins,andmembranefusionproteinsareindicatedbythekb(kilobasepair)inthes.entericase rovartyphimurium strainlt2genome.arowscorespondtothelengthsanddirectionsofthe genes.aminoacididentitybetweenhomologousproteinsins.entericaande.coliareindicated asnumbersunderthegenenames.

EfluxSystem -(ΔacrB) AcrAB AcrD AcrEF MdtABC MdsABC EmrAB MdfA MdtK MacAB EM 28 28 8 NOV 2 256 6 28 6 8 6 2 2 2 Table2. DrugresistanceprofilesofdrugefluxsystemsinSalmonela TC CP 8 MICfortheΔacrBmutant-overproducingefluxsystems(μg/mL) NA 8 NFLX DXR ACR CV EBR MB R6G TPP 0.06 8 32 2 6 6 8 32 0.3 > 28> 52 28 > 52> 52> 52 52 0.06 8 32 2 6 6 8 32 0.3 > 28 52 32 > 52> 52> 52 52 0.06 8 32 2 6 6 8 32 0.06 8 28 6 28 256 6 6 0.06 8 32 2 6 6 6 32 0.3 32 32 2 6 6 8 32 0.3 6 256 2 6 6 8 32 0.06 8 32 2 6 6 8 32 BENZ SDS DOC 28 20,000 6 > 52> 0,000 > 52 0,000 6 > 52 0,000 52 0,000 8 256 20,000 28> 0,000 28 20,000 28 20,000 28 20,000 Abbreviations:EM,erythromycin;NOV,novobiocin;TC,tetracycline;CP,chloramphenicol;NA,nalidixicacid;NFLX,norfloxacin;DXR, doxorubicin;acr,acriflavine;cv,crystalviolet;ebr,ethidium bromide;mb,methyleneblue;r6g,rhodamine6g;tpp,tetraphenylphosphonium bromide;benz,benzalkonium chloride;sds,sodium dodecylsulfate;doc,sodium deoxycholate. Strain Table3. SusceptibilityofSalmoneladrugtransporter-deletedstrainstotoxiccompounds EM NOV Wild-type 28 256 ΔacrAB acref acrd mdtabc mdsabc emrab mdfamdtkmacab TC NA NFLX DXR 0.06 ACR MIC(μg/mL) CV EBR MB R6G TPP BENZ 0.25 > 28> 52 256 > 52> 52> 52> 52 32 2 32 6 8 32 6 SDS DOC > 52> 0,000 Abbreviations:EM,erythromycin;NOV,novobiocin;TC,tetracycline;NA,nalidixicacid;NFLX,norfloxacin;DXR,doxorubicin;ACR,acriflavine;CV,crystalviolet;EBR,ethidium bromide;mb,methyleneblue;r6g,rhodamine6g;tpp,tetraphenylphosphonium bromide; BENZ,benzalkonium chloride;sds,sodium dodecylsulfate;doc,sodium deoxycholate. MICdeterminationswererepeatedatleastthreetimes. 32 33 Fig.6. RoleofdrugefluxsystemsinSalmonelavirulence. ThisfigureshowsthesurvivalrateofmiceinfectedwithSalmo nelastrains.balb/cmicewereinoculatedoralywith0 5 col onyformingunitofdiferentsalmonelastrainsasindicated. mdsabc mds Salmonella macab β

Fig.7. Transportofdrugsandiron-chelatorbydrugefluxsystems. TheexpressionacrDandmdtABCdrugefluxgenesareregulatedbyFur.FurcontrolsironhomeostasisinmostGram-negative bacteria.wefoundthattheseefluxsystemstransportnotonlydrugsbutalsothesiderophoreenterobactin. V

Salmonella enterica Escherichia coli Escherichia coli Escherichia coli β Escherichia coli Salmonella Escherichia coli Salmonella enterica Escherichia coli evga Escherichia coli Escherichia coli

Escherichia coli Escherichia coli Escherichia coli